EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD

Elda Cristina Villaseñor-Tapia iD, Adriana Franco-Acevedo iD, Rebeca Rosas-Campos, Juan Armendariz-Borunda iD

Pharmaceutics · 09.05.2026 · 18 (5) · 584

DOI: 10.3390/pharmaceutics18050584 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 09.05.2026. Verfasst von Elda Cristina Villaseñor-Tapia und 3 weiteren Autor:innen. Beteiligte Einrichtung: EMCS, Tecnologico de Monterrey, Zapopan 45201, Jalisco, Mexico. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tecnológico de Monterrey.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent global health concern driven by metabolic imbalance and excess caloric intake, leading to hepatic steatosis, inflammation, and fibrosis that may progress to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, or hepatocellular carcinoma. Current management relies primarily on lifestyle interventions and, in advanced stages, pharmacological therapies; however, long-term outcomes remain limited due to variable efficacy and poor sustainability. Recent advances in pharmacotherapy, including GLP-1 receptor agonists, THR-β agonists and SGLT2 inhibitors, have shown clinically meaningful improvements in metabolic parameters and hepatic steatosis, although their impact on fibrosis and long-term disease modification remains uncertain. In parallel, genomic and nanotechnology-based strategies (such as RNA-based therapies and nanoparticle delivery systems) have emerged as promising approaches to enhance drug stability, targeting, and therapeutic precision. Despite these advances, most emerging strategies remain at preclinical or early translational stages, with significant challenges related to safety, scalability, regulatory approval, and long-term efficacy. In this context, this review provides an integrative synthesis of pharmacological, genomic, and nanotechnology-based therapies, highlighting their mechanisms, limitations, and translational potential. Future research should focus on well-designed clinical trials, standardized evaluation frameworks, and the development of personalized therapeutic approaches. The convergence of these strategies may enable more effective and durable interventions for MASLD.

Schlagwörter

Stichwörter der Autor:innen

MASH/NASHMASLD/NAFLDdrug delivery systemslivernanomedicinenanoparticles/nanotherapiespersonalized medicinepharmacological therapies

Autor:innen und Institutionen

  • EMCS, Tecnologico de Monterrey, Zapopan 45201, Jalisco, Mexico.
  • Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, CUCS, Guadalajara 44340, Jalisco, Mexico.

ORCID-Profile: Elda Cristina Villaseñor-Tapia, Adriana Franco-Acevedo, Juan Armendariz-Borunda

Förderung

  • Tecnológico de Monterrey

Zitieren

APA

Villaseñor-Tapia, E. C., Franco-Acevedo, A., Rosas-Campos, R., & Armendariz-Borunda, J. (2026). Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD. Pharmaceutics, 18(5), 584. https://doi.org/10.3390/pharmaceutics18050584

Vancouver

Villaseñor-Tapia EC, Franco-Acevedo A, Rosas-Campos R, Armendariz-Borunda J. Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD. Pharmaceutics. 2026;18(5):584. doi:10.3390/pharmaceutics18050584

BibTeX
@article{VillaseorTapia2026,
  author = {Villaseñor-Tapia, Elda Cristina and Franco-Acevedo, Adriana and Rosas-Campos, Rebeca and Armendariz-Borunda, Juan},
  title = {Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {5},
  pages = {584},
  doi = {10.3390/pharmaceutics18050584}
}
Kostenlos starten →